Lisraya is a drug owned by Priovant Therapeutics Inc. It is protected by 2 US drug patents filed in 2026 out of which none have expired yet. Lisraya's patents will be open to challenges from 27 August, 2030. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 19, 2035. Details of Lisraya's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9663526 | Aminopyrimidinyl Compounds |
Aug, 2035
(8 years from now) | Active |
| US11197867 | Aminopyrimidinyl Compounds |
Aug, 2035
(8 years from now) | Active |
FDA has granted several exclusivities to Lisraya. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Lisraya, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Lisraya.
Exclusivity Information
Lisraya holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Lisraya's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2031 |
US patents provide insights into the exclusivity only within the United States, but
Lisraya is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Lisraya's family patents as well as insights into
ongoing legal events
on those patents.
Lisraya's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lisraya's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 19, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lisraya Generics:
There are no approved generic versions for Lisraya as of now.
About Lisraya
Lisraya is a drug owned by Priovant Therapeutics Inc. Lisraya uses Brepocitinib Tosylate as an active ingredient. Lisraya was launched by Priovant in 2026.
Approval Date:
Lisraya was approved by FDA for market use on 27 August, 2026.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Lisraya is 27 August, 2026, its NCE-1 date is estimated to be 27 August, 2030.
Active Ingredient:
Lisraya uses Brepocitinib Tosylate as the active ingredient. Check out other Drugs and Companies using Brepocitinib Tosylate ingredient
Dosage:
Lisraya is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 30MG BASE | TABLET | Prescription | ORAL |